Clinical Trials Logo

High-Risk Resectable NSCLC clinical trials

View clinical trials related to High-Risk Resectable NSCLC.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03732664 Completed - Clinical trials for High-Risk Resectable NSCLC

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Start date: October 1, 2018
Phase: Phase 1
Study type: Interventional

The proposed study will evaluate the safety and feasibility of preoperative administration nivolumab in patients with high-risk resectable NSCLC, and will facilitate a comprehensive exploratory characterization of the tumor immune milieu and circulating immune cells and soluble factors in these patients. Data obtained in this study will provide valuable information for planning further prospective clinical trials of anti-PD-1 or anti-PD-L1 in NSCLC, both in the peri-operative and advanced disease setting.